Goldman Sachs Group Inc F Star Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	BUY	$4.09 - $6.86 $125,080 - $209,792	30,582 Added 41.27%	104,690 $661,000
Q4 2022 Feb 13, 2023	BUY	$4.09 - $6.86 $125,080 - $209,792	30,582 Added 41.27%	104,690 $661,000
Q3 2022 May 14, 2024	BUY	$5.41 - $6.74 $291,934 - $363,703	53,962 Added 267.85%	74,108 $379,000
Q3 2022 Nov 10, 2022	BUY	$5.41 - $6.74 $291,934 - $363,703	53,962 Added 267.85%	74,108 $0
Q2 2022 May 14, 2024	BUY	$2.18 - $6.39 $43,918 - $128,732	20,146 New	20,146 $126,000
Q2 2022 Aug 15, 2022	SELL	$2.18 - $6.39 $29,770 - $87,261	-13,656 Reduced 40.4%	20,146 $126,000
Q1 2022 May 16, 2022	BUY	$2.77 - $5.36 $93,631 - $181,178	33,802 New	33,802 $120,000

44.7K

Ticker FSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,584,700
Description
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck c...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.